PPD Biotech pan­el: Five lead­ers in the Boston hub eval­u­ate the top trends — and where we’re all head­ed in the next 5 years

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Sup­ply and De­mand Ex­pec­ta­tions and Im­bal­ances

7 years ago

Swedish Biotech Dex­Tech Med­ical shoots for bil­lion dol­lar prostate can­cer mar­ket — con­cludes phI­Ib study ear­ly

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Bull­ish Run to Con­tin­ue Amidst Signs of Greater Risk Aver­sion

7 years ago

Min­i­mal Resid­ual Dis­ease: A Prog­nos­tic Fac­tor Mov­ing the Nee­dle in Pa­tient Care

8 years ago

For­get about greed, Pres­i­dent Trump: the vil­lain re­spon­si­ble for high drug prices is in­ef­fi­cien­cy

8 years ago

The Evolv­ing Over­all Sur­vival Ex­pec­ta­tions of Pa­tients with Re­lapsed or Re­frac­to­ry Mul­ti­ple Myelo­ma

8 years ago

The win­ners and losers of the Swedish biotech in­dus­try IPO fren­zy

8 years ago

How as­set sup­ply and de­mand is shap­ing bio­phar­ma­ceu­ti­cal deal­mak­ing

9 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2017: In­flu­ences and Hot Spots

9 years ago

CVS Leads Trend To­ward Less Ex­pen­sive Neu­trope­nia Treat­ments

9 years ago
First page Previous page 891011
A service from the Financial Times